Item 7.01 Regulation FD Disclosure.

On April 14, 2022, Magenta Therapeutics, Inc. issued a press release regarding certain corporate and clinical updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed:



99.1      Press Release dated April 14, 2022.

104     Cover Page Interactive Data File (embedded within the Inline XBRL document).



                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses